LT3597189T - Kristaliniai junginia - Google Patents

Kristaliniai junginia

Info

Publication number
LT3597189T
LT3597189T LTEP19196556.5T LT19196556T LT3597189T LT 3597189 T LT3597189 T LT 3597189T LT 19196556 T LT19196556 T LT 19196556T LT 3597189 T LT3597189 T LT 3597189T
Authority
LT
Lithuania
Prior art keywords
crystalline compounds
crystalline
compounds
Prior art date
Application number
LTEP19196556.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Anthony Alexander Mckinney
Franklin Bymaster
Walter Piskorski
Fred J. Fleitz
Yonglai Yang
David A. Engers
Valeriya Smolenskaya
Venkat Kusukuntla
Original Assignee
Otsuka America Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.
Publication of LT3597189T publication Critical patent/LT3597189T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
LTEP19196556.5T 2015-06-17 2016-06-17 Kristaliniai junginia LT3597189T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562181174P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
LT3597189T true LT3597189T (lt) 2022-07-11

Family

ID=57546597

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP19196556.5T LT3597189T (lt) 2015-06-17 2016-06-17 Kristaliniai junginia

Country Status (25)

Country Link
US (6) US9708261B2 (enExample)
EP (3) EP4049997A1 (enExample)
JP (5) JP6896651B2 (enExample)
KR (1) KR102593783B1 (enExample)
CN (3) CN117466800A (enExample)
AU (2) AU2016279075C1 (enExample)
CA (2) CA3200692A1 (enExample)
CY (1) CY1125352T1 (enExample)
DK (1) DK3597189T3 (enExample)
ES (1) ES2922158T3 (enExample)
HK (1) HK1247125A1 (enExample)
HR (1) HRP20220829T1 (enExample)
HU (1) HUE059348T2 (enExample)
LT (1) LT3597189T (enExample)
MX (2) MX387591B (enExample)
MY (1) MY194868A (enExample)
NZ (2) NZ739044A (enExample)
PH (1) PH12017502324A1 (enExample)
PL (1) PL3597189T3 (enExample)
PT (1) PT3597189T (enExample)
SA (1) SA517390552B1 (enExample)
SG (1) SG10201911417PA (enExample)
SI (1) SI3597189T1 (enExample)
TW (1) TWI751998B (enExample)
WO (1) WO2016205762A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3080080A4 (en) * 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos
US11149004B2 (en) 2017-12-11 2021-10-19 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of EB-1020, processes for preparation and use thereof
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法
US12698260B2 (en) * 2021-05-31 2026-08-04 Assia Chemical Industries Ltd. Solid state form of centanafadine HCL and process for preparation thereof
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005117630A (ru) 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CA2619817A1 (en) 2004-08-18 2006-03-02 Dov Pharmaceutical, Inc. Thermodynamically stable polymorph of an azabicyclohexane
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) * 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
EP2819516B1 (en) * 2011-07-30 2019-12-25 Otsuka America Pharmaceutical, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
EP3080080A4 (en) 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
ES2922158T3 (es) 2015-06-17 2022-09-09 Otsuka America Pharmaceutical Inc Compuestos cristalinos

Also Published As

Publication number Publication date
WO2016205762A1 (en) 2016-12-22
JP2026083082A (ja) 2026-05-19
TW201800392A (zh) 2018-01-01
EP3597189B1 (en) 2022-06-01
AU2021200314B2 (en) 2022-08-04
HUE059348T2 (hu) 2022-11-28
EP3310352A4 (en) 2019-03-13
JP2018517742A (ja) 2018-07-05
JP2021138747A (ja) 2021-09-16
US11299458B2 (en) 2022-04-12
PL3597189T3 (pl) 2022-07-25
EP3310352A1 (en) 2018-04-25
KR20180014830A (ko) 2018-02-09
US9708261B2 (en) 2017-07-18
CN117088802A (zh) 2023-11-21
SG10201911417PA (en) 2020-01-30
US9856217B2 (en) 2018-01-02
AU2016279075B2 (en) 2020-10-22
CN117466800A (zh) 2024-01-30
SI3597189T1 (sl) 2022-08-31
DK3597189T3 (da) 2022-06-27
ES2922158T3 (es) 2022-09-09
CA3200692A1 (en) 2016-12-22
TWI751998B (zh) 2022-01-11
JP7583851B2 (ja) 2024-11-14
NZ739044A (en) 2022-08-26
US20210198198A1 (en) 2021-07-01
US20170334850A1 (en) 2017-11-23
AU2021200314A1 (en) 2021-03-18
HRP20220829T1 (hr) 2022-12-23
HK1247125A1 (zh) 2018-09-21
RU2018101244A (ru) 2019-07-22
JP6896651B2 (ja) 2021-06-30
US20260138950A1 (en) 2026-05-21
US20180194726A1 (en) 2018-07-12
CA2989431A1 (en) 2016-12-22
CN107921021A (zh) 2018-04-17
MY194868A (en) 2022-12-21
EP4049997A1 (en) 2022-08-31
US10280141B2 (en) 2019-05-07
MX2017016430A (es) 2018-11-09
MX387591B (es) 2025-03-18
US20160368871A1 (en) 2016-12-22
CA2989431C (en) 2023-08-29
JP2023071978A (ja) 2023-05-23
EP3597189A1 (en) 2020-01-22
US20200039934A1 (en) 2020-02-06
KR102593783B1 (ko) 2023-10-25
MX2020009949A (es) 2020-10-16
PT3597189T (pt) 2022-07-05
AU2016279075C1 (en) 2021-04-01
JP2025022896A (ja) 2025-02-14
CY1125352T1 (el) 2025-05-09
NZ776973A (en) 2022-11-25
PH12017502324A1 (en) 2018-06-25
SA517390552B1 (ar) 2022-04-13
JP7244575B2 (ja) 2023-03-22
RU2018101244A3 (enExample) 2019-12-23
AU2016279075A1 (en) 2018-02-01
US10800740B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
DK3360864T3 (da) Pyrimidinforbindelse
DK3316969T3 (da) Antibakterielle forbindelser
LT3134402T (lt) 4-amino-imidazochinolino junginiai
HUE042964T2 (hu) Szubsztituált dihidro-izokinolinon vegyületek
HUE050732T2 (hu) Új vegyületek
PT3298027T (pt) Compostos depsipéptidos antelmínticos
HUE049921T2 (hu) Gyomirtó propinil-fenil-vegyületek
EP3354638A4 (en) PHTHALODINITRILVERBINDUNG
BR112017005883A2 (pt) compostos herbicidas
BR112016030730A2 (pt) Composto
LT3464336T (lt) Junginiai
EP3227309A4 (en) CRYSTALLINE DIFUCOSYLLACTOSIS
BR112017017193A2 (pt) compostos herbicidas
LT3362444T (lt) Junginiai
EP3299355A4 (en) PHTHALODINITRILVERBINDUNG
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3277690T3 (da) Spirocykliske forbindelser
DK3597189T3 (da) Krystallinske forbindelser
BR112016029117A2 (pt) compostos herbicidas
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
MA43275A (fr) Composé de pyranodipyridine
BR112018001062A2 (pt) compostos inovadores
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
LT3331885T (lt) Junginiai